January 17, 2023 16:05 ET ROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company’s Management will provide a corporate update and participate in one-on-one […]
January 09, 2023 08:00 ET -Clinical trial is being conducted at St. James’s University Hospital, United Kingdom, in collaboration with the University of Leeds- ROCKVILLE, Md., Jan. 09, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas
Title: Sidoti Virtual Conference Presentation Date: Thursday, December 8, 2022 Time: 9:15 AM ET Link: Click here
Sidoti Virtual Conference Presentation Read More »
November 10, 2022 16:45 ET –Reported encouraging clinical data supporting the differentiated mode-of action of Theriva’s novel oncolytic adenovirus (OV) platform– –Received clearance from the Federal Drug Administration (FDA) and Spanish Competent Authority (AEMPS) for the planned Phase 2 clinical trial of systemically administered VCN-01 in Pancreatic Ductal Adenocarcinoma (PDAC) patients– –Reported positive safety and
November 03, 2022 08:00 ET – Initiation of Cohort 2 Follows a Positive Review of Safety and Pharmacokinetic (PK) Data from Cohort 1 by an Independent Data and Safety Monitoring Committee – – Cohort 2 Patient Dosing Highlights Momentum Across the Theriva Oncology-Focused Clinical Pipeline – ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) — Theriva
-Webinar to feature presentation from immunotherapy experts Michael Aaron Morse, M.D., and Arsen Osipov, M.D., on Monday, November 7th at 11 a.m. ET- October 31, 2022 08:00 ET ROCKVILLE, Md., Oct. 31, 2022 (GLOBE NEWSWIRE) — Theriva Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat
Rebrand solidifies sharpened clinical development strategy to advance unique oncolytic viruses optimized for intravenous (IV) administration October 12, 2022 08:00 ET ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) — Theriva Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”) is the new name of Synthetic Biologics, Inc. (NYSE American: SYN). The new name, logo and
Synthetic Biologics Rebrands as Theriva Biologics Read More »
September 30, 2022 08:00 ET Preclinical results demonstrated that topotecan treatment enhanced VCN-01 oncolytic activity against retinoblastoma ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the presentation of new data from
September 27, 2022 08:00 ET – The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2 – ROCKVILLE, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat
The information in this website contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended, on Theriva™ Biologics’ current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology
